Mannkind Corp (MNKD) has gained an incredible ~40% in the past 5 days as the biotech awaits FDA's final call on it's experimental inhaled insulin drug, Afrezza. The PDUFA is scheduled for Dec. 29, 2010.
Keep your eyes open for some beaten down put options if Afrezza does get approved. This would be a play similar to what we've done with
MELA and
OREX. Essentially we want to capitalize on the post-approval drop in Mannkind's share price.
No comments:
Post a Comment